Figure 7
Figure 7. The phagocytosis of platelets depends on exposure of phosphatidylserine, on expression of P-selectin and β2 integrins. The percentage of neutrophils with adherent (■) and internalized () platelets (A) and their MPO content (B) were evaluated. (Left panels) Neutrophils were challenged with resting platelets (TRAP-6−) or with activated platelets (TRAP-6+) or with activated platelets treated with recombinant annexin A5 (15 μg/mL; TRAP-6+, annexin A5). (Middle panels) Neutrophils were challenged with activated platelets (TRAP-6+) either in the presence of irrelevant control mAb, or of EDTA, or of anti–P-selectin mAb (anti P-sel) or of anti–PSGL-1 mAb (anti PSGL-1). (Right panels) Neutrophils were challenged with activated platelets (TRAP-6+) either in the presence of irrelevant control mAb, or of anti-GPIbα mAb (anti-GPIbα), or of mAb against the β2 subunit binding site (anti-CD18), or against the Mac-1 binding site (anti Mac-1). All mAbs were incubated with the relevant cell fraction at a 20 μg/mL final concentration 5 minutes before the assay. Adhesion, phagocytosis, and MPO release are expressed as mean ± SEM of 6 to 16 independent experiments. ***P < .001; *P < .005, significantly different from control.

The phagocytosis of platelets depends on exposure of phosphatidylserine, on expression of P-selectin and β2 integrins. The percentage of neutrophils with adherent (■) and internalized () platelets (A) and their MPO content (B) were evaluated. (Left panels) Neutrophils were challenged with resting platelets (TRAP-6−) or with activated platelets (TRAP-6+) or with activated platelets treated with recombinant annexin A5 (15 μg/mL; TRAP-6+, annexin A5). (Middle panels) Neutrophils were challenged with activated platelets (TRAP-6+) either in the presence of irrelevant control mAb, or of EDTA, or of anti–P-selectin mAb (anti P-sel) or of anti–PSGL-1 mAb (anti PSGL-1). (Right panels) Neutrophils were challenged with activated platelets (TRAP-6+) either in the presence of irrelevant control mAb, or of anti-GPIbα mAb (anti-GPIbα), or of mAb against the β2 subunit binding site (anti-CD18), or against the Mac-1 binding site (anti Mac-1). All mAbs were incubated with the relevant cell fraction at a 20 μg/mL final concentration 5 minutes before the assay. Adhesion, phagocytosis, and MPO release are expressed as mean ± SEM of 6 to 16 independent experiments. ***P < .001; *P < .005, significantly different from control.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal